Advanced Urothelial Carcinoma
Advanced Urothelial Carcinoma
Advertisement
Emily MenendezAdvanced Urothelial Carcinoma | April 12, 2024
A case study studied the results of 4 patients with locally advanced or oligometastatic UC with complete response on imaging.
Read More
Emily MenendezAdvanced Urothelial Carcinoma | March 14, 2024
While ICIs have become a novel treatment option for mUC, attrition rates may affect their impact on long-term survival.
Guru P. Sonpavde, MDAdvanced Urothelial Carcinoma | March 12, 2024
Dr. Sonpavde provides an overview of the potential of nivo/gem-cis for patients with mUC who are ineligible for EV/pembro.
Zachary BessetteAdvanced Urothelial Carcinoma | March 7, 2024
Approval came as a result of the CheckMate 901 study, a randomized trial that enrolled 608 patients with metastatic UC.
Emily MenendezAdvanced Urothelial Carcinoma | March 6, 2024
Patients who received EV over chemotherapy maintained their HRQOL levels and experienced delayed HRQOL deterioration.
Emily MenendezAdvanced Urothelial Carcinoma | February 28, 2024
Patients with mutations in the UGT1A1 gene can experience adverse events when treated with irinotecan-based therapies.
Thomas Powles, MBBS, MRCP, MDAdvanced Urothelial Carcinoma | March 7, 2024
Dr. Powles offers his thoughts on the latest OS data from EV-302 for patient subgroups and immune-related toxicity.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | February 12, 2024
The potential for sequencing erdafitinib and EV for patients with FGFR2/3-altered disease is considered.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | February 12, 2024
The impact of squamous and other histologies on outcomes with EV are dissected.
Vadim Koshkin, MDAdvanced Urothelial Carcinoma | February 12, 2024
The design of UNITE, patients sampled, and outcomes with EV after switch maintenance avelumab are explored.
Emily MenendezAdvanced Urothelial Carcinoma | February 12, 2024
With a high response rate and manageable toxicity, further research into the use of SG in patients with mUC is warranted.
Petros Grivas, MD, PhDASCO GU Symposium 2024 | February 5, 2024
Dr. Grivas describes the advancements in the discussion around avelumab maintenance at this year's meeting.
Guru P. Sonpavde, MDASCO GU Symposium 2024 | February 4, 2024
Dr. Sonpavde provides a detailed overview of 2 of the bladder cancer trials of note: AMBASSADOR and PemCab.
Shilpa Gupta, MDASCO GU Symposium 2024 | January 27, 2024
Dr. Gupta details some of her latest research and describes the importance of multiple new initiatives in bladder cancer.
Zachary BessetteASCO GU Symposium 2024 | February 5, 2024
Improved outcomes in patients with previously untreated la/mUC after EV/pembro, even in poor prognosis patient subgroups.
Zachary BessetteASCO GU Symposium 2024 | February 1, 2024
Adjuvant pembrolizumab demonstrates improvement in DFS for patients with high-risk MIUC after radical surgery.
Zachary BessetteASCO GU Symposium 2024 | January 25, 2024
Prolonged avelumab first-line maintenance treatment is associated with stable PROs for those with aUC.
Zachary BessetteASCO GU Symposium 2024 | February 1, 2024
An early-stage trial highlights the antitumor activity from erdafitinib plus EV for mUC with FGFR2/3 genetic alterations.
Katy MarshallASCO GU Symposium 2024 | February 1, 2024
Patients received pembrolizumab 200 mg every 3 weeks and cabozantinib 40 mg daily.
Zachary BessetteAdvanced Urothelial Carcinoma | February 16, 2024
The FDA has approved erdafitinib for adult patients with mUC and susceptible FGFR3 genetic alterations.
Advertisement
Advertisement
Advertisement